The Findings on Bone Scintigraphy in Patients With Suspected Tumor-Induced Osteomalacia Should Not Be Overlooked

被引:9
作者
Wang, Ling [1 ]
Zhang, Shu [1 ]
Jing, Hongli [1 ]
Chen, Libo [1 ]
Wang, Zhenghua [1 ]
Li, Fang [1 ]
机构
[1] Peking Union Med Coll Hosp, Dept Nucl Med, 1 Shuaifuyuan,Wangfujing St, Beijing 100730, Peoples R China
基金
中国国家自然科学基金;
关键词
bone scintigraphy; bone pain; hypophosphatemia; tumor-induced osteomalacia (TIO); ONCOGENIC OSTEOMALACIA; HODGKIN-LYMPHOMA; CELL CARCINOMA; GA-68-DOTATATE; DIAGNOSIS; PET/CT; MANAGEMENT; SCAN;
D O I
10.1097/RLU.0000000000002012
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Tumor-induced osteomalacia (TIO) is a chronic, devastating disease. The causative tumor is usually a small benign one that is very difficult to localize. Because the presenting symptoms include diffuse bone pain, a bone scintigraphy is commonly performed to determine the cause of the pain before TIO is suspected. In this retrospective investigation, we tried to assess whether bone scintigraphy acquired will be helpful in the eventual identification of the culprit tumor. Methods The images of bone scan and clinical charts of total 91 patients with confirmed TIO were retrospectively reviewed. The image findings were compared with the results of other imaging studies, surgical notes, histopathologic examinations and clinical follow-ups. Results In 76.9% (70 of 91) of the patients, the findings of bone scintigraphy did not correspond to the sites of the causative tumors, which were subsequently located. However, in 23.1% of the patients (21 of 91), the sites of the causative tumors corresponded to one of the abnormal technetium 99m-methyl diphosphonate activity on bone scintigraphy. More importantly, 6 tumors corresponded to the dominant activity on bone scintigraphy. Conclusions Although findings of whole-body scintigraphy are nonspecific in patients with TIO, careful evaluation of bone scintigraphy results can be helpful in guiding further evaluation in some patients.
引用
收藏
页码:239 / 245
页数:7
相关论文
共 36 条
[1]  
Abate Ejigayehu G, 2016, Bone Rep, V5, P81, DOI 10.1016/j.bonr.2015.11.004
[2]  
Agaimy A, 2017, AM J SURG PATHOL, V41, P1371, DOI 10.1097/PAS.0000000000000890
[3]   Hypophosphatemia: Clinical consequences and management [J].
Brunelli, Steven M. ;
Goldfarb, Stanley .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (07) :1999-2003
[4]  
Casari S, 2003, CLIN EXP RHEUMATOL, V21, P493
[5]   Tumor-induced osteomalacia [J].
Chong, William H. ;
Molinolo, Alfredo A. ;
Chen, Clara C. ;
Collins, Michael T. .
ENDOCRINE-RELATED CANCER, 2011, 18 (03) :R53-R77
[6]   68Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia [J].
El-Maouche, Diala ;
Sadowski, Samira M. ;
Papadakis, Georgios Z. ;
Guthrie, Lori ;
Cottle-Delisle, Candice ;
Merkel, Roxanne ;
Millo, Corina ;
Chen, Clara C. ;
Kebebew, Electron ;
Collins, Michael T. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (10) :3575-3581
[7]  
Florenzano Pablo, 2017, Bone Rep, V7, P90, DOI 10.1016/j.bonr.2017.09.002
[8]   Bone and In-111 octreotide imaging in oncogenic osteomalacia - A case report [J].
Garcia, CA ;
Spencer, RP .
CLINICAL NUCLEAR MEDICINE, 2002, 27 (08) :582-583
[9]  
GARTY I, 1985, EUR J NUCL MED, V10, P362
[10]   PET/CT With 68Ga-DOTA-TATE for Diagnosis of Neuroendocrine Differentiation in Patients With Castrate-Resistant Prostate Cancer [J].
Gofrit, Ofer Nathan ;
Frank, Stephen ;
Meirovitz, Amichay ;
Nechushtan, Hovav ;
Orevi, Marina .
CLINICAL NUCLEAR MEDICINE, 2017, 42 (01) :1-6